fludarabine has been researched along with arsenic trioxide in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asslaber, D; Greil, R; Hamacher, F; Heyder, C; Holler, C; Merkel, O; Papak, C; Prokesch, A; Scheideler, M; Stöcher, M; Tinhofer, I; Trajanoski, Z | 1 |
| Aguilera-Montilla, N; Amigo-Jiménez, I; Bailón, E; García-Marco, JA; García-Pardo, A; Ugarte-Berzal, E | 1 |
| Amigo-Jiménez, I; García-Marco, JA; García-Pardo, A; Lozano-Santos, C; Nova-Gurumeta, S; Pérez-Sanz, N | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
1 review(s) available for fludarabine and arsenic trioxide
| Article | Year |
|---|---|
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
3 other study(ies) available for fludarabine and arsenic trioxide
| Article | Year |
|---|---|
Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Caspases; Chromosome Deletion; Chromosomes, Human, Pair 17; Drug Resistance, Neoplasm; Enzyme Activation; Female; Free Radical Scavengers; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Oxidative Stress; Oxides; Poly(ADP-ribose) Polymerases; Prognosis; Reactive Oxygen Species; Superoxide Dismutase; Vidarabine | 2008 |
Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
Topics: Aged; Aged, 80 and over; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Membrane; Down-Regulation; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Hyaluronan Receptors; Integrin alpha4beta1; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Matrix Metalloproteinase 9; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxides; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Transcription, Genetic; Up-Regulation; Vidarabine | 2014 |
Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Drug Synergism; Enzyme Inhibitors; Female; Growth Inhibitors; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; MAP Kinase Signaling System; Middle Aged; Oxides; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Vidarabine | 2015 |